Endometrial Cancer: Patient Presentation and Initial Workup
Expert perspective on the presentation of endometrial cancer, followed by advice on providing optimal workup and diagnosis.
EP: 1.Case Overview: A 64-Year-Old Woman With dMMR Metastatic Endometrial Cancer
EP: 2.Endometrial Cancer: Patient Presentation and Initial Workup
EP: 3.Systemic Therapy Options for Patients With Metastatic Endometrial Cancer
EP: 4.Dostarlimab Therapy in Recurrent Metastatic Endometrial Cancer: The GARNET Trial
EP: 5.Considerations for Second-Line Treatment Selection for Patients With Metastatic EC
EP: 6.Recurrent Metastatic EC: Common Immune-Related Adverse Events And Patient Discussions
EP: 7.Metastatic Endometrial Cancer: Future Directions in Care
Transcript:
Bhavana Pothuri, MD: The typical patient that we see with endometrial cancer is obese, hypertensive, and usually has a well differentiated or grade 1 endometrioid histology. Since I'm in New York City, I also see a very racially and ethnically diverse patient population and many of these patients unfortunately present with more advanced-stage disease and more of the higher risk histologic subtypes, such as uterine serous cancer.
Typically about a quarter to a third of patients have mismatch repair deficiency. I recommend all patients with endometrial cancer have mismatch repair testing. In my practice, our pathologists routinely test for mismatch repair deficiency by immunohistochemistry [IHC] for MLH1, MSH2, MSH6 and PMS2. And if MLH1 is absent on immunohistochemistry, they reflexively get tested for MLH1 hypermethylation. In terms of other molecular testing, if your mismatch repair IHC is intact you can consider MSI [microsatellite instability] testing for completeness sake and so that you don't miss any patients.
Transcript edited for clarity.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More
Ghamande Reviews Latest Chemoimmunotherapy Trials for Endometrial Cancer
March 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sharad A. Ghamande, MD, discussed the significance of the NRG-GY018/KEYNOTE-868 and RUBY trials of immune checkpoint inhibitor plus chemotherapy in patients with advanced endometrial cancer.
Read More
